NanoViricides, Inc. (NYSE:NNVC) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC raised its stake in shares of NanoViricides, Inc. (NYSE:NNVC) by 20.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 102,100 shares of the company’s stock after purchasing an additional 17,600 shares during the period. Renaissance Technologies LLC’s holdings in NanoViricides were worth $176,000 at the end of the most recent reporting period.

Separately, Moss Adams Wealth Advisors LLC purchased a new stake in NanoViricides during the second quarter valued at about $26,000. 10.30% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of NanoViricides from a “hold” rating to a “sell” rating in a research report on Wednesday, July 17th.

NanoViricides Trading Up 8.8 %

Shares of NNVC stock opened at $1.49 on Monday. NanoViricides, Inc. has a twelve month low of $1.00 and a twelve month high of $3.59. The company has a market capitalization of $17.60 million, a PE ratio of -1.82 and a beta of 0.94. The firm has a fifty day simple moving average of $1.70 and a 200-day simple moving average of $1.78.

NanoViricides (NYSE:NNVC) last posted its quarterly earnings results on Friday, September 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01.

About NanoViricides

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.